Abstract:
PURPOSE: A composition containing an Ecklonia cava extract treated with an enzyme and a method for manufacturing the same are provided to suppress tyrosinase and melanogenesis. CONSTITUTION: A composition for skin whitening contains 0.001-20 wt% of an Ecklonia cava extract treated with an enzyme as an active ingredient. The enzyme is a cell wall degrading enzyme including celluclast or protease including pectinase. The composition is a cosmetic composition or a pharmaceutical composition. A method for preparing the composition comprises: a step of treating Ecklonia cava with an enzyme; and a step of extracting the enzyme-treated Ecklonia cava with water, an organic solvent, or a mixture thereof.
Abstract:
PURPOSE: A benzoic acid amide compound is provided to have excellent a skin-whitening effect without side effects by suppressing melanin generation and decreasing tyrosinase activity. CONSTITUTION: A benzoic acid amide compound, an isomer thereof, pharmaceutically-acceptable salt thereof, a prodrug thereof, a hydrate thereof, or a solvate thereof is represented by chemical formula 1. In the chemical formula 1: each of R1, R3, and R4 is independently selected from hydrogen, hydroxy, C1-C5 alkoxy, C3-C6 cycloalkoxy, aryloxy, and C1-C15 haloalkoxy; R2 is selected from hydrogen, C1-C5 alkyl, C3-C6 cycloalkyl, aryl, and C1-C5 haloalkyl; and n is an integer from 1-5.
Abstract:
PURPOSE: A compound is provided to treat heart diseases, pain, and hair growth-associated diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating pharmacological stimulation and/or abnormal expression of vaniloid receptor 1(VR1) contains a compound of chemical formula I, II, III, or IV, isomer thereof, or pharmaceutically acceptable salt and pharmaceutically acceptable carrier. The pharmaceutical composition is applied to rat, mouse, livestock, and human. The pharmaceutical composition is used by rectal, intravenous, intramuscular, or subcutaneous administration.
Abstract:
본 발명은 바닐로이드 수용체 (Vanilloid Receptor 1 ; VR1 ; TRPV1)의 길항제로서 신규한 화합물 또는 약제학적으로 허용가능한 그의 염; 및 이를 함유하는 약제학적 조성물에 관한 것이다. 본 발명의 화합물 또는 조성물은 통증, 편두통, 관절통, 신경통, 신경병증, 신경손상, 피부질환, 과민성방광, 과민성대장증후군, 변실금, 호흡기질환, 피부, 눈 또는 점막의 자극, 위십이지장궤양, 염증성질환, 이(耳)질환, 및 심장질환 등의 예방 및 치료에 유용하다. 바닐로이드 수용체 길항제, N-페닐벤즈아마이드 유도체